Active Ingredient History
Siplizumab (MEDI-507) is an investigational monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and has been tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia, Sickle Cell (Phase 1/Phase 2)
Chimera (Phase 1/Phase 2)
Diabetes Mellitus, Type 1 (Phase 2)
Graft vs Host Disease (Phase 1)
Kidney Diseases (Phase 1)
Kidney Failure, Chronic (Phase 2)
Kidney Transplantation (Phase 2)
Leukemia (Phase 2)
Liver Transplantation (Phase 2)
Lymphoma (Phase 2)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 1)
Lymphoproliferative Disorders (Phase 1)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoplasms (Phase 1)
Psoriasis (Phase 2)
Renal Insufficiency (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue